Dow Jones 30 Stocks SEC Filings — May 07, 2026

07-05-2026

Hennessy Capital Investment Corp. VII announced a proposed business combination with ONE Nuclear Energy LLC, targeting closing in Q2 2026 with post-merger listing on NASDAQ under ticker ONEN. ONE Nuclear develops, owns, and operates baseload power using fast-track gas generation and advanced nuclear SMRs, securing three priority development sites in Texas, New Mexico, and Washington with 1 GW targeted online by end of 2029 from a 15 GW total potential pipeline across 75+ sites. The management team has delivered over $50 billion in infrastructure projects, supported by strategic partners including Rolls-Royce, BP Energy, and Black & Veatch.

• ·LOI signed in July 2025; raised Hennessy VII in late January 2025
• ·First gas revenues projected for 2028; Texas site: 1 GW gas by 2029, 2 GW nuclear SMR by 2034; New Mexico: initial 1 GW gas expandable to 10 GW; Washington: up to 6 GW SMR
• ·Strategic relationships with Rolls-Royce (gas and SMR), Westinghouse, X-energy, TerraPower; BP Energy for offtake; Black & Veatch for EPC
• ·Sites selected for >1000 acres, gas/water access, proximity to data centers in ERCOT (Texas), high-growth areas

07-05-2026

MasterCraft Boat Holdings, Inc. reported Q3 FY2026 net sales of $78.2 million, up 3.0% YoY from $76.0 million, driven by favorable model mix and pricing, though partially offset by lower unit volumes (MasterCraft down 3.1% to 409 units). Adjusted EBITDA rose to $10.7 million (up from $7.5 million) and gross margin expanded 420 basis points, but GAAP loss from continuing operations was $0.7 million (vs. $3.8 million profit) due to $9.2 million higher operating expenses from transaction costs related to the pending Marine Products merger. The company ended the quarter with $84.6 million in cash and investments and reaffirmed FY2026 guidance excluding the merger.

• ·Special shareholder meeting scheduled for May 12, 2026, to approve Marine Products merger announced February 5, 2026.
• ·Q3 FY2026 operating expenses increased $9.2 million YoY to $20.8 million, driven by merger-related and ERP costs.
• ·9M FY2026 income from continuing operations $5.4 million vs. $5.3 million prior year.
• ·Cash and equivalents $75.4 million at March 29, 2026, up from $28.9 million at June 30, 2025.

07-05-2026

Vera Therapeutics reported a Q1 2026 net loss of $121.0 million, significantly wider than $51.7 million in Q1 2025, driven by elevated R&D expenses of $86.0 million (up from $41.3 million) and G&A expenses of $39.1 million (up from $15.9 million) amid pre-commercial preparations. Cash, cash equivalents, and marketable securities decreased to $596.8 million from $714.6 million at year-end 2025, with net cash used in operations rising to $106.5 million from $54.4 million YoY, though management states it is sufficient to fund beyond potential atacicept approval and launch. Positively, the FDA granted priority review to the atacicept BLA for IgAN with a PDUFA target date of July 7, 2026, positioning the company for a potential mid-2026 U.S. commercial launch.

• ·FDA Breakthrough Therapy Designation received for atacicept in IgAN.
• ·Initial results from PIONEER trial expected Q2 2026.
• ·Pivotal two-year eGFR data from ORIGIN 3 trial expected Q1 2027.
• ·Promotion of Matt Skelton to Chief Commercial Officer; appointments of Jane Wright-Mitchell as Chief Legal Officer and Christopher Hite to Board.

07-05-2026

Optimum Communications reported Q1 2026 total revenue of $2.07 billion, down 4.0% YoY, driven by residential revenue declines of 6.5% to $1.56 billion and broadband PSU net losses of 64k, resulting in a net loss of $2,884.1 million primarily due to a $2.7 billion non-cash impairment charge. Positively, Adjusted EBITDA reached $789.0 million (-1.3% YoY) with margin expansion to 38.2% (+110 bps YoY), mobile lines achieved 52k net additions (strongest in 6 years) boosting revenue 35% to $50 million, and cash capital expenditures fell 13.6% to $307.7 million. Operational efficiencies supported gross margin expansion to 69.4% (+60 bps YoY), though net cash from operating activities declined 9.2% to $170.3 million.

• ·Consolidated net leverage 7.5x L2QA as of March 31, 2026
• ·Weighted average cost of debt 6.8%, weighted average life 3.1 years for consolidated Optimum Communications
• ·Lightpath refinanced all outstanding indebtedness via asset-backed securitization on March 3, 2026
• ·Cablevision Litchfield and CSC Optimum entered $1.1 billion incremental term loan on January 12, 2026
• ·96% of total footprint had 1 Gig or higher speeds available end Q1 2026
• ·Residential mobile penetration of broadband base 8.8% end Q1 2026 (up from 6.3% Q1 2025)

07-05-2026

PSQ Holdings reported Q1 2026 net revenue from continuing operations of $8.2 million, up 167% YoY from $3.1 million, with operating expenses down 18% ($2.0 million reduction), operating loss improved 34% to $6.1 million, and revenue per headcount surging 287% to $173,583. However, net loss widened 45% to $6.5 million due to $7.1 million decrease in fair value gains on warrant and earnout liabilities, loss per share rose 20% to $0.12, and discontinued operations revenue remained flat at $3.7 million YoY. The company reduced headcount 41% to 47 full-time employees amid operational restructuring, targeting $8.0 million annualized savings.

• ·Payments Gross Merchandise Volume (GMV) exceeded $186 million in Q1 2026, a record.
• ·Credit GMV increased 32% (period unspecified).
• ·Income from discontinued operations, net of tax: $26,710 in Q1 2026 vs. $2.4 million loss in Q1 2025.
• ·Cash and cash equivalents: $10,057,059 as of March 31, 2026 (down from $14,644,384 at Dec 31, 2025).
• ·Total assets: $54,354,878 as of March 31, 2026 (down from $59,678,408 at Dec 31, 2025).

07-05-2026

Angelini Pharma S.p.A. has agreed to acquire Catalyst Pharmaceuticals, Inc. (CPRX) for $31.50 per share in cash, totaling approximately $4.1 billion USD (equivalent to 3.5 billion euros), representing premiums of 21% to the unaffected closing price and 28% to the 30-day VWAP as of April 22, 2026. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 subject to stockholder approval, regulatory clearances, and customary conditions, marking Angelini Pharma's U.S. market entry. Separately, Catalyst resolved all pending FIRDAPSE patent litigation with Hetero USA, Inc. and affiliates via a settlement agreement.

• ·Acquisition financed with cash and debt; no financing condition.
• ·Catalyst to become wholly owned subsidiary of Angelini Pharma post-merger.
• ·Financial advisors: Centerview Partners (lead for Angelini), J.P. Morgan (sole for Catalyst).
• ·Catalyst's 2026 annual stockholder meeting suspended due to transaction.
• ·Settlement with Hetero terminates all FIRDAPSE patent litigation; to be submitted to FTC and DOJ.

07-05-2026

Resolute Holdings reported Q1 2026 GAAP net income attributable to common stockholders of $61.5M ($7.19 diluted EPS) versus a $3.4M loss ($0.39 loss per share) YoY, and Non-GAAP Fee-Related Earnings of $5.9M ($0.69 per share) versus a $0.6M loss ($0.07 loss per share), driven by management fees rising to $12.9M from $1.1M due to the new Husky Holdings agreement and CompoSecure growth. However, consolidated results showed an operating loss of $5.8M versus $25.6M income, with net sales at $407.8M but weighed down by SG&A expenses of $162.6M (up from $28.9M), interest expense $30.1M (from $3.5M), and a $106.8M loss on debt extinguishment, leading to operating cash use of $116.8M versus $18.4M provided. The company repurchased $38.0M in common shares amid balance sheet expansion from GPGI Holdings consolidation.

• ·Consolidated balance sheet total assets increased to $6,215.0M from $333.4M due to GPGI Holdings consolidation.
• ·Long-term debt increased to $2,178.3M from $169.8M.
• ·Cash and cash equivalents decreased to $113.1M from $161.4M QoQ.
• ·Equity-based compensation expense $2.3M in Q1 2026 vs $6.0M YoY.

07-05-2026

Kontoor Brands reported stronger Q1 2026 results with revenue from continuing operations at $613 million, up 45% YoY driven by the Helly Hansen acquisition (16% pro-forma growth) and Wrangler growth of 4% globally (U.S. +1%, international +20%), alongside adjusted gross margin expansion of 470 basis points to 50.6%. The company raised its full-year 2026 outlook to $3.41-$3.46 billion in total revenue (continuing operations $2.66-$2.71 billion) and $6.60-$6.70 adjusted EPS, announced a planned divestiture of the Lee business (Q1 revenue $195 million, FY ~$750 million as discontinued operations), and authorized a $750 million share repurchase program. While operating income from continuing operations grew 60% to $87 million adjusted, SG&A expenses increased to $224 million or 36.5% of revenue, reflecting investments and Helly Hansen integration.

• ·Q1 2026 adjusted EPS from continuing operations: $1.06 (includes $0.26 from Helly Hansen, $0.11 overhead reclass from Lee)
• ·FY2026 adjusted gross margin outlook: 48.3% to 48.5% (+180-200 bps YoY)
• ·FY2026 adjusted operating income outlook from continuing operations: $411-$418M (+15-17% YoY)
• ·Q1 end: $493M available under Revolving Credit Facility; net leverage targeted below 1.5x by FY2026 end
• ·Quarterly dividend: $0.53 per share, payable June 18, 2026 (record June 8, 2026)
• ·IEEPA tariff reversal: $29M of $49M COGS reduction related to 2025; outlook assumes 15% reciprocal tariffs (10% from Feb 24, 2026)

07-05-2026

AvePoint reported first quarter 2026 total revenue of $117.2 million, up 26% YoY (20% constant currency), driven by SaaS revenue growth of 35% YoY (29% constant currency) to $93.4 million, with ARR reaching $435.2 million, up 26% YoY (23% FX-adjusted). GAAP operating income improved to $12.7 million (10.9% margin from 3.5%), and cash from operations was $24.3 million versus $0.5 million prior year. However, GAAP gross margin declined to 72.8% from 74.3%, term license and support revenue fell to $9.3 million from $13.2 million, and cash equivalents decreased to $444.1 million from $481.1 million.

• ·Dollar-based gross retention rate of 89%; net retention rate of 111% (110% FX-adjusted).
• ·Q2 2026 guidance: Total revenue $120.3M-$122.3M (+19% YoY midpoint); Non-GAAP operating income $18.7M-$19.7M.
• ·FY 2026 guidance raised: ARR $523.4M-$529.4M (+26% YoY midpoint); Total revenue $509.4M-$515.4M (+22% YoY midpoint); Non-GAAP operating income $91.5M-$94.5M.
• ·Renewed share repurchase program for 3 years up to $150M.
• ·Conference call on May 07, 2026 at 4:30pm ET.

07-05-2026

Gevo reported Q1 2026 revenue of $43 million, up from $29 million in Q1 2025, and Non-GAAP Adjusted EBITDA of $9 million versus negative $15 million YoY, driven by strong low-carbon ethanol production of 18 million gallons and carbon capture of 46 thousand metric tons. However, net loss remained flat at $(22) million or $(0.09) per share due to $11 million in bond extinguishment and debt costs, with cash and equivalents declining to $78.9 million from $81.2 million at year-end 2025. The company targets $30 million Adjusted EBITDA for 2026 (up from $17 million in 2025) and a $40 million annualized run-rate by year-end, alongside progress on ATJ-30 financing and GND expansion.

• ·Executed preliminary agreement with Ara Energy for co-investment in GND expansion to double capacity, targeting startup in 2028.
• ·Received non-binding indications of interest for private capital financing of ATJ-30 project; FEL-3 engineering expected Q2 2026.
• ·Secured take-or-pay offtake agreements covering about half of ATJ-30 capacity.
• ·GND debottlenecking on track for 75 million gallons annual low-carbon ethanol capacity starting 2027.

07-05-2026

Evommune reported first quarter 2026 financial results with cash, cash equivalents, and investments of $307.0 million as of March 31, 2026, up from $216.7 million at December 31, 2025, expected to fund operations through 2028. However, revenue fell to $0 from $3.0 million YoY, research and development expenses increased to $17.3 million from $14.4 million, general and administrative expenses rose to $6.6 million from $3.7 million, and net loss widened to $21.7 million from $14.6 million. The company highlighted pipeline progress, with Phase 2b enrollment complete for EVO756 in CSU (top-line June 2026, N=160) and AD (top-line 3Q26, N=120), plans for EVO756 migraine trial mid-2026, and EVO301 subcutaneous Phase 2b in AD mid-2027.

• ·Presentations at FOCIS (June 9-12, 2026), AHS (June 4-7, 2026), and SID (May 13-16, 2026) on MRGPRX2 and IL-18 data.
• ·EVO301 additional indications under evaluation: ulcerative colitis, cardiovascular-related inflammatory conditions, food allergy.
• ·Detailed balance sheet: Cash, cash equivalents and short-term investments $211.5M (Mar 31, 2026) vs $149.2M (Dec 31, 2025); Long-term investments $95.5M vs $67.5M.

07-05-2026

Fold Holdings, Inc. filed an S-3 shelf registration statement on May 7, 2026, to register up to 1,040,000 shares of common stock (approximately 2.1% of outstanding shares as of May 4, 2026) for resale by SATS Credit Fund L.P., consisting of 520,000 initial commitment shares and 520,000 shares issuable upon potential renewal of a note. The company will receive no proceeds from these sales. While enabling liquidity for the selling stockholder, substantial sales could depress the market price of the company's common stock, which closed at $1.34 on May 4, 2026.

• ·Purchase Agreement dated February 25, 2026, with SATS Credit Fund L.P.
• ·Registration Rights Agreement entered into with SATS Credit Fund on February 25, 2026.
• ·Company classified as non-accelerated filer, smaller reporting company, and emerging growth company.
• ·Principal executive offices: 2942 North 24th Street, Suite 115, #42035, Phoenix, Arizona 85016.
• ·Business address: 2929 Arch St., Suite 1703, Philadelphia, PA 19103.
• ·Former names: FTAC Emerald Acquisition Corp. (name change November 16, 2021), Emerald ESG Acquisition Corp. (name change October 19, 2021).

07-05-2026

07-05-2026

General Fusion announced presentations by CEO Greg Twinney and Chief Strategy Officer Megan Wilson at key May 2026 conferences including Web Summit Vancouver (over 20,000 attendees expected), Canaccord Genuity’s Nuclear Nexus, and B. Riley Securities Institutional Investor Conference, amid its proposed business combination with Spring Valley Acquisition Corp. III (SVAC), targeted to close mid-2026 with Nasdaq listing as GFUZ. The press release highlights progress on its LM26 fusion machine but emphasizes forward-looking risks such as merger completion uncertainties, regulatory approvals, technological commercialization challenges, and potential failure to achieve fusion milestones.

• ·Business Combination Agreement dated January 21, 2026
• ·SVAC to continue to British Columbia, amalgamate with NewCo, and rename to General Fusion Group Ltd.
• ·Web Summit sessions: New Energy Summit Keynote on May 13 at 11:50 a.m. PT; Startup University Fireside Chat on May 14 at 12:10 p.m. PT
• ·LM26 operates at 50% commercial-scale diameter and targets plasma heating to 1 keV then 10 keV, and Lawson criterion
• ·General Fusion founded in 2002 and headquartered in Vancouver, Canada

07-05-2026

Booking Holdings Inc. executed an Officers’ Certificate on May 7, 2026, for the issuance of $750,000,000 aggregate principal amount of 5.375% Senior Notes due 2036, following an underwriting agreement dated May 5, 2026, with Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC as representatives. The Senior Notes are general senior unsecured obligations, bearing semi-annual interest at 5.375% starting November 7, 2026, and maturing on May 7, 2036, unless redeemed earlier. No period-over-period financial metrics are provided in the filing.

• ·Senior Notes are redeemable prior to February 7, 2036 (Par Call Date) at the greater of 100% of principal or present value of remaining payments discounted at Treasury Rate plus 15 basis points, plus accrued interest.
• ·Indenture includes customary events of default, with acceleration possible by Trustee or holders of 25% of outstanding principal upon non-bankruptcy defaults.
• ·Offering conducted pursuant to shelf Registration Statement (File No. 333-273678).

07-05-2026

07-05-2026

07-05-2026

07-05-2026

Carnival PLC filed an 8-K on 2026-05-07 disclosing the termination of a material definitive agreement (Item 1.02), completion of an acquisition or disposition of assets (Item 2.01), notice of delisting or failure to satisfy listing standards (Item 3.01), unregistered sales of equity securities (Item 3.02), material modifications to rights of security holders (Item 3.03), changes in control of the registrant (Item 5.01), and amendments to articles of incorporation or bylaws (Item 5.03), along with Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). No specific details on transaction parties, structure, valuation, or financial impacts are disclosed. These events indicate a significant corporate restructuring, potentially involving a change in ownership or going private, but lack of quantitative metrics prevents assessment of positive or negative impacts.

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

Con Edison reported 2026 first quarter GAAP net income for common stock of $924 million or $2.55 per share, up from $791 million or $2.26 per share in 2025 first quarter, primarily driven by a $134 million after-tax gain on the sale of its equity interest in Mountain Valley Pipeline, LLC for total consideration of $357.5 million. However, adjusted earnings (non-GAAP) were $790 million or $2.18 per share, slightly down from $792 million or $2.26 per share in the prior year, reflecting declines in CECONY operations partially offset by O&R gains. The company reaffirmed its 2026 adjusted EPS guidance range of $6.00 to $6.20 per share.

• ·CECONY variations: higher electric/gas rate base (+$19M net of tax), but higher O&M (-$28M) and interest (-$9M) led to net decline of $12M.
• ·O&R: electric/gas base rate increases (+$8M net of tax), offset by higher interest (-$3M), net +$7M.
• ·Con Edison Transmission: gain on MVP sale +$134M after tax, transaction costs -$2M, other +$1M.
• ·2026 adjusted EPS guidance excludes MVP gain (-$0.37/share after-tax) and other items.

07-05-2026

Bar Harbor Bankshares filed an 8-K on May 07, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific matters voted on, vote outcomes, numerical results, or other details such as for/against/abstain shares are disclosed in the provided filing information. This is a standard mandatory disclosure following a shareholder meeting, with no financial or operational metrics mentioned.

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

Claritev Corporation reported Q1 2026 revenues of $244.7 million, up 5.8% YoY from $231.3 million, and Adjusted EBITDA of $146.9 million, up 3.4% YoY from $142.1 million, though the Adjusted EBITDA margin declined to 60.0% from 61.4%. However, net loss widened to $73.6 million from $71.3 million YoY, net cash used in operating activities increased to $45.8 million from $30.1 million, and free cash flow deteriorated to $(92.5) million from $(68.9) million. The company narrowed its FY2026 revenue guidance low-end to $985 million-$1 billion (from $980 million-$1 billion), with other metrics unchanged.

• ·FY2026 guidance: Capital expenditures $160 million to $170 million; Effective tax rate 24% to 28%; Free Cash Flow $0 million to $10 million
• ·Q1 2026 ended March 31, 2026; Investor Day held in March 2026
• ·Strong Q1 bookings from core offerings, provider, and government verticals

07-05-2026

Privia Health reported strong Q1 2026 results with total revenue up 25.8% YoY to $603.8M, Practice Collections +14.6% to $914.8M, Adjusted EBITDA +36.3% to $36.7M, Implemented Providers +13.6% to 5,535, and Value-Based Care Attributed Lives +26.5% to 1,606,000. However, GAAP net income declined 27.4% YoY to $3.1M due to higher stock compensation and taxes, and net cash used in operating activities increased to $49.5M from $24.1M. The company reiterated full-year 2026 guidance for most metrics while raising Attributed Lives outlook to 1,600,000-1,625,000.

• ·Cash and cash equivalents decreased to $419.5M from $479.7M at Dec 31, 2025.
• ·Full-year 2026 guidance: Adjusted EBITDA $145M-$155M (unchanged), Practice Collections $3,650M-$3,750M (unchanged).

07-05-2026

Citizens Financial Services, Inc. reported net income of $10,376 thousand for the three months ended March 31, 2026, a 36.1% YoY increase from $7,621 thousand, supported by net interest income growth to $26,113 thousand (+13.5% YoY) and lower interest expense ($14,164 thousand vs. $16,012 thousand). However, total assets contracted 1.2% QoQ to $3,026,478 thousand, loans declined 2.3% QoQ to $2,275,328 thousand (net of $22,894 thousand allowance), and comprehensive income fell to $8,071 thousand from prior comprehensive gains due to a $2,305 thousand net OCI loss. Deposits rose 2.7% QoQ to $2,441,185 thousand, while borrowed funds dropped sharply 35.7% to $198,738 thousand.

• ·Noninterest-bearing deposits declined QoQ to $509,638 thousand from $516,657 thousand.
• ·Bank owned life insurance increased to $74,071 thousand from $51,501 thousand, reflecting $22,000 thousand purchase.
• ·EPS basic $2.16 for Q1 2026 vs. $1.59 YoY.
• ·Cash dividends paid $2,402 thousand at $0.500 per share.

07-05-2026

Avient reported Q1 2026 sales of $847.4 million, up 3% YoY from $826.6 million, driven by a 5% favorable FX impact implying ~2% organic decline; adjusted EPS grew 9% to $0.83 exceeding guidance, with adjusted EBITDA margins expanding 20 basis points to 17.7%. GAAP EPS improved to $0.61 from a ($0.22) loss, aided by prior-year special items including a large ERP impairment. Full-year 2026 guidance remains unchanged at adjusted EPS $2.93-$3.17 and adjusted EBITDA $555-$585 million, with Q2 adjusted EPS guided at $0.89 (11% YoY growth), though H2 outlook is less certain.

• ·Q1 2026 special items after-tax: $5.5M expense ($0.06 per share); Q1 2025: $75.7M expense ($0.82 per share) including $86.3M ERP impairment
• ·Cash dividends declared: $0.2750 per share (Q1 2026) vs $0.2700 (Q1 2025)
• ·Weighted-average diluted shares: 91.9M (Q1 2026) vs 91.5M (Q1 2025)
• ·Total assets: $5,944.8M (Mar 31, 2026) vs $6,025.6M (Dec 31, 2025)

07-05-2026

Celsius Holdings reported record Q1 2026 revenue of $782.6 million, up 138% YoY from $329.3 million, driven by Alani Nu ($368.1 million revenue) and Rockstar Energy ($66.6 million), with North America revenue surging 144% to $747.3 million and International up 55% to $35.3 million. However, gross margin declined 400 basis points to 48.3% due to lower-margin acquired brands, and Rockstar Energy retail sales fell 13% YoY while CELSIUS brand revenue grew modestly 6% YoY. Net income increased 148% to $110.1 million, adjusted EBITDA rose 181% to $195.5 million, and the company repurchased $24.1 million in shares.

• ·Celsius Holdings portfolio contributed 45% of the zero-sugar U.S. energy category’s $800 million growth in Q1 2026.
• ·Approximate 20.9% dollar share of the U.S. RTD energy category in Q1 2026.
• ·CELSIUS brand held 9.9% dollar share, Alani Nu 9.0%, Rockstar Energy 2.0% in U.S. RTD energy category L13W ended 3/29/2026.
• ·SG&A expenses increased 95% to $234.6 million (30.0% of revenue vs 36.5% prior year); adjusted SG&A 26.4% of revenue.
• ·Cash and cash equivalents increased to $549.2 million from $398.9 million at year-end 2025.

07-05-2026

First Advantage reported record Q1 2026 revenues of $385.2 million, up 8.6% YoY from $354.6 million, with Adjusted EBITDA rising 14.3% to $105.3 million (27.3% margin) and Adjusted Net Income up 48.0% to $45.1 million. GAAP net income improved to $2.2 million (0.6% margin) from a $41.2 million loss in Q1 2025, though the margin remains modest. The company repurchased $19.5 million in shares during the quarter (plus $13.8 million subsequently) and made voluntary debt prepayments totaling $50 million early in 2026, while reaffirming full-year guidance.

• ·Customer retention rate of 97%.
• ·Share repurchase program authorization of $100 million.
• ·Positive momentum in retail & e-commerce, transportation & logistics, and gig economy verticals.
• ·Conference call held on May 7, 2026, at 8:30 a.m. ET.

07-05-2026

Avalo Therapeutics entered into an underwriting agreement on May 5, 2026, to issue and sell 19,730,000 shares of common stock at $17.75 per share and 1,400,000 pre-funded warrants at $17.749 each, with the underwriters fully exercising their option for an additional 3,169,500 shares, expecting net proceeds of approximately $405.0 million. As of March 31, 2026, the company had preliminary cash, cash equivalents, and short-term investments of $82.0 million, and together with the offering proceeds, expects to fund operations into 2029, primarily for advancing abdakibart through Phase 3 topline data release. The offering is expected to close on May 7, 2026, subject to customary conditions.

• ·Pre-Funded Warrants exercisable at $0.001 per share or via cashless exercise, with ownership limit initially set at 4.99% or 9.99%, adjustable up to 19.99% upon 61 days' notice.
• ·Underwriting option exercisable for 30 days after Prospectus Supplement dated May 5, 2026.
• ·Prospectus Supplement filed with SEC on May 6, 2026, under Form S-3 effective January 20, 2026.